{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:41:43Z","timestamp":1773297703305,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,2,5]],"date-time":"2008-02-05T00:00:00Z","timestamp":1202169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1038\/ijo.2008.3","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T10:54:46Z","timestamp":1202295286000},"page":"863-870","source":"Crossref","is-referenced-by-count":37,"title":["Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats"],"prefix":"10.1038","volume":"32","author":[{"given":"I","family":"Kunz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M K","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bourson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fisseha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,5]]},"reference":[{"key":"BFijo20083_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1210\/er.2005-0009","volume":"27","author":"U Pagotto","year":"2006","unstructured":"Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R . The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73\u2013100.","journal-title":"Endocr Rev"},{"key":"BFijo20083_CR2","first-page":"389","volume":"5","author":"SC Black","year":"2004","unstructured":"Black SC . Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004; 5: 389\u2013394.","journal-title":"Curr Opin Investig Drugs"},{"key":"BFijo20083_CR3","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0006-2952(00)00447-0","volume":"60","author":"JP Meschler","year":"2000","unstructured":"Meschler JP, Kraichely DM, Wilken GH, Howlett AC . Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem Pharmacol 2000; 60: 1315\u20131323.","journal-title":"Biochem Pharmacol"},{"key":"BFijo20083_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","volume":"350","author":"M Rinaldi-Carmona","year":"1994","unstructured":"Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240\u2013244.","journal-title":"FEBS Lett"},{"key":"BFijo20083_CR5","doi-asserted-by":"publisher","first-page":"PL113","DOI":"10.1016\/S0024-3205(98)00322-1","volume":"63","author":"G Colombo","year":"1998","unstructured":"Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL . Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63: PL113\u2013PL117.","journal-title":"Life Sci"},{"key":"BFijo20083_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1463-1326.2004.00374.x","volume":"7","author":"B Poirier","year":"2005","unstructured":"Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005; 7: 65\u201372.","journal-title":"Diabetes Obes Metab"},{"key":"BFijo20083_CR7","doi-asserted-by":"publisher","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","volume":"284","author":"C Ravinet Trillou","year":"2003","unstructured":"Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345\u2013R353.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"BFijo20083_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.neulet.2003.10.035","volume":"354","author":"AN Verty","year":"2004","unstructured":"Verty AN, McGregor IS, Mallet PE . Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 2004; 354: 217\u2013220.","journal-title":"Neurosci Lett"},{"key":"BFijo20083_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00213-002-1384-8","volume":"167","author":"SP Vickers","year":"2003","unstructured":"Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA . Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa\/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003; 167: 103\u2013111.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFijo20083_CR10","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"JP Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121\u20132134.","journal-title":"N Engl J Med"},{"key":"BFijo20083_CR11","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jacc.2005.12.067","volume":"47","author":"EV Gelfand","year":"2006","unstructured":"Gelfand EV, Cannon CP . Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006; 47: 1919\u20131926.","journal-title":"J Am Coll Cardiol"},{"key":"BFijo20083_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761\u2013775.","journal-title":"JAMA"},{"key":"BFijo20083_CR13","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"AJ Scheen","year":"2006","unstructured":"Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF . Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660\u20131672.","journal-title":"Lancet"},{"key":"BFijo20083_CR14","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389\u20131397.","journal-title":"Lancet"},{"key":"BFijo20083_CR15","first-page":"53","volume":"8","author":"RA Smith","year":"2005","unstructured":"Smith RA, Fathi Z . Recent advances in the research and development of CB(1) antagonists. IDrugs 2005; 8: 53\u201366.","journal-title":"IDrugs"},{"key":"BFijo20083_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/sj.ijo.0802847","volume":"29","author":"YL Liu","year":"2005","unstructured":"Liu YL, Connoley IP, Wilson CA, Stock MJ . Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)\/Lep(ob) mice. Int J Obes Relat Metab Disord 2005; 29: 183\u2013187.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFijo20083_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pbb.2006.06.001","volume":"84","author":"ZD Thornton-Jones","year":"2006","unstructured":"Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM et al. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006; 84: 353\u2013359.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFijo20083_CR18","first-page":"E826","volume":"293","author":"AW Herling","year":"2007","unstructured":"Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J, Muller G et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol 2007; 293: E826\u2013E832.","journal-title":"Am J Physiol"},{"key":"BFijo20083_CR19","first-page":"1103","volume":"20","author":"B Costa","year":"1999","unstructured":"Costa B, Colleoni M . SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Acta Pharmacol Sin 1999; 20: 1103\u20131106.","journal-title":"Acta Pharmacol Sin"},{"key":"BFijo20083_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s007020070043","volume":"107","author":"NA Darmani","year":"2000","unstructured":"Darmani NA, Pandya DK . Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 2000; 107: 931\u2013945.","journal-title":"J Neural Transm"},{"key":"BFijo20083_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0091-3057(03)00168-0","volume":"75","author":"TU Jarbe","year":"2003","unstructured":"Jarbe TU, DiPatrizio NV, Li C, Makriyannis A . The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav 2003; 75: 809\u2013821.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFijo20083_CR22","first-page":"586","volume":"277","author":"DR Compton","year":"1996","unstructured":"Compton DR, Aceto MD, Lowe J, Martin BR . In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996; 277: 586\u2013594.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFijo20083_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/00008877-199907000-00010","volume":"10","author":"JM Masserano","year":"1999","unstructured":"Masserano JM, Karoum F, Wyatt RJ . SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav Pharmacol 1999; 10: 429\u2013432.","journal-title":"Behav Pharmacol"},{"key":"BFijo20083_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/00001756-199701200-00023","volume":"8","author":"M Navarro","year":"1997","unstructured":"Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8: 491\u2013496.","journal-title":"Neuroreport"},{"key":"BFijo20083_CR25","doi-asserted-by":"publisher","first-page":"10529","DOI":"10.1073\/pnas.1834309100","volume":"100","author":"MM Ibrahim","year":"2003","unstructured":"Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100: 10529\u201310533.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFijo20083_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/0149-7634(94)90056-6","volume":"18","author":"PC Even","year":"1994","unstructured":"Even PC, Mokhtarian A, Pele A . Practical aspects of indirect calorimetry in laboratory animals. Neurosci Biobehav Rev 1994; 18: 435\u2013447.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFijo20083_CR27","doi-asserted-by":"publisher","first-page":"E399","DOI":"10.1152\/ajpcell.1990.258.3.C399","volume":"258","author":"DC Simonson","year":"1990","unstructured":"Simonson DC, DeFronzo RA . Indirect calorimetry: methodological and interpretative problems. Am J Physiol 1990; 258: E399\u2013E412.","journal-title":"Am J Physiol"},{"key":"BFijo20083_CR28","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1073\/pnas.98.4.2005","volume":"98","author":"J Fruebis","year":"2001","unstructured":"Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005\u20132010.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFijo20083_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.clnu.2004.04.010","volume":"23","author":"M Gil-Campos","year":"2004","unstructured":"Gil-Campos M, Canete RR, Gil A . Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963\u2013974.","journal-title":"Clin Nutr"},{"key":"BFijo20083_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.molmed.2005.06.010","volume":"11","author":"JK Sethi","year":"2005","unstructured":"Sethi JK, Vidal-Puig A . Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005; 11: 344\u2013347.","journal-title":"Trends Mol Med"},{"key":"BFijo20083_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1055\/s-2006-925401","volume":"38","author":"N Perwitz","year":"2006","unstructured":"Perwitz N, Fasshauer M, Klein J . Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 2006; 38: 356\u2013358.","journal-title":"Horm Metab Res"},{"key":"BFijo20083_CR32","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1124\/mol.63.4.908","volume":"63","author":"M Bensaid","year":"2003","unstructured":"Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908\u2013914.","journal-title":"Mol Pharmacol"},{"key":"BFijo20083_CR33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/mol.105.015040","volume":"69","author":"M Gary-Bobo","year":"2006","unstructured":"Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M . The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69: 471\u2013478.","journal-title":"Mol Pharmacol"},{"key":"BFijo20083_CR34","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/oby.2002.138","volume":"10","author":"N Stefan","year":"2002","unstructured":"Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Ravussin E, Weyer C et al. Plasma adiponectin levels are not associated with fat oxidation in humans. Obes Res 2002; 10: 1016\u20131020.","journal-title":"Obes Res"},{"key":"BFijo20083_CR35","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1096\/fj.04-3177fje","volume":"19","author":"O Jbilo","year":"2005","unstructured":"Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567\u20131569.","journal-title":"FASEB J"},{"key":"BFijo20083_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/(SICI)1098-2396(200001)35:1<8::AID-SYN2>3.0.CO;2-Y","volume":"35","author":"T Rubino","year":"2000","unstructured":"Rubino T, Vigano D, Zagato E, Sala M, Parolaro D . In vivo characterization of the specific cannabinoid receptor antagonist SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 2000; 35: 8\u201314.","journal-title":"Synapse"},{"issue":"Suppl 4","key":"BFijo20083_CR37","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S1098-3597(06)80041-4","volume":"8","author":"S Engeli","year":"2006","unstructured":"Engeli S, Jordan J . The endocannabinoid system: body weight and metabolic regulation. Clin Cornerstone 2006; 8 (Suppl 4): S24\u2013S35.","journal-title":"Clin Cornerstone"},{"key":"BFijo20083_CR38","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","volume":"54","author":"S Engeli","year":"2005","unstructured":"Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838\u20132843.","journal-title":"Diabetes"},{"key":"BFijo20083_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tem.2006.11.006","volume":"18","author":"I Matias","year":"2007","unstructured":"Matias I, Di Marzo V . Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27\u201337.","journal-title":"Trends Endocrinol Metab"},{"key":"BFijo20083_CR40","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.2337\/db06-0504","volume":"55","author":"C Doyon","year":"2006","unstructured":"Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006; 55: 3403\u20133410.","journal-title":"Diabetes"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ijo20083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijo20083","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijo20083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:19:05Z","timestamp":1684430345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo20083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["BFijo20083"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2008.3","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,5]]}}}